Point72 Asia (Singapore) Pte. Ltd. Immunovant, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Immunovant, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 15,076 shares of IMVT stock, worth $414,740. This represents 0.04% of its overall portfolio holdings.
Number of Shares
15,076Holding current value
$414,740% of portfolio
0.04%Shares
2 transactions
Others Institutions Holding IMVT
# of Institutions
214Shares Held
81.1MCall Options Held
557KPut Options Held
704K-
Deep Track Capital, LP Greenwich, CT9.73MShares$268 Million8.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.83MShares$188 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.84MShares$161 Million2.47% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.22% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.16MShares$142 Million0.05% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...